Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QD64 | ISIN: US50107A1043 | Ticker-Symbol: N/A
NASDAQ
18.06.25 | 21:59
0,880 US-Dollar
0,00 % 0,000
1-Jahres-Chart  (nicht börsennotiert)
KRONOS BIO INC Chart 1 Jahr

Aktuelle News zur KRONOS BIO

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.06.NSE - Kronos Bio, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities7
20.06.Kronos Bio, Inc. - 8-K, Current Report1
05.06.Kronos Bio, Inc. - 8-K, Current Report3
08.05.Kronos Bio, Inc. - 10-Q, Quarterly Report3
05.05.Concentra Biosciences Agrees to Acquire Kronos Bio1
01.05.Concentra To Acquire Kronos Bio4
KRONOS BIO Aktie jetzt für 0€ handeln
01.05.Kronos Bio, Inc. - 8-K, Current Report2
01.05.Kronos Bio stimmt Übernahme durch Concentra Biosciences zu5
01.05.Kronos Bio to be acquired by Concentra Biosciences1
01.05.Kronos Bio agrees to Concentra Biosciences acquisition1
01.05.Kronos Bio, Inc.: Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right12CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and...
► Artikel lesen
25.04.Kronos Bio, Inc. - 10-K/A, Annual Report1
10.04.Kronos Bio, Inc. - 8-K, Current Report4
18.03.Kronos Bio GAAP EPS of -$0.43, revenue of $2.27M2
18.03.Kronos Bio Inc Q4 Sales Decline1
18.03.Kronos Bio, Inc. - 10-K, Annual Report2
18.03.Kronos Bio, Inc. - 8-K, Current Report2
18.03.Kronos Bio, Inc.: Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results167SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial...
► Artikel lesen
27.11.24Kronos Bio, Inc.: Kronos Bio Announces CEO Transition and Reduction in Force218- Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO - - Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO - SAN MATEO, Calif. and CAMBRIDGE, Mass....
► Artikel lesen
14.11.24Kronos Bio, Inc.: Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024135- Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten